

Publications with DharmaconTM Edit-RTM CRISPR-Cas9 reagents

These publications demonstrate the application of CRISPR-Cas9 genome engineering techniques for target gene knockout or precise knockin using DharmaconTM Edit-RTM CRISPR-Cas9 reagents or custom RNA synthesis.

2018

1. A. Cluse, I. Nikolic, *et al.* A Comprehensive Protocol Resource for Performing Pooled shRNA and CRISPR Screens. *Methods Mol Biol.* **1725**, 201–227 (2018). doi: 10.1007/978-1-4939-7568-6_17
2. K. S. Kim, N. Maio, *et al.* Cytosolic HSC20 integrates de novo iron-sulfur cluster biogenesis with the CIAO1-mediated transfer to recipients. *Hum Mol Genet.* **27**, 827–852 (2018). doi: 10.1093/hmg/ddy004
3. S. Melnik, D. Dvornikov, *et al.* Cancer cell specific inhibition of Wnt/ β -catenin signaling by forced intracellular acidification. *Cell Discov.* **4**, 37 (2018). doi: 10.1038/s41421-018-0033-2
4. S. J. Pettitt, D. B. Krastev, *et al.* Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance. *Nat Commun.* **9**, 1849 (2018). doi: 10.1038/s41467-018-03917-2
5. P. G. Ziros, I. G. Habeos, *et al.* NFE2-Related Transcription Factor 2 Coordinates Antioxidant Defense with Thyroglobulin Production and Iodination in the Thyroid Gland. *Thyroid.* **28**, 780–798 (2018). doi: 10.1089/thy.2018.0018

2017

1. M. Basila, M. L. Kelley, *et al.* Minimal 2'-O-methyl phosphorothioate linkage modification pattern of synthetic guide RNAs for increased stability and efficient CRISPR-Cas9 gene editing avoiding cellular toxicity. *PLoS One.* **12**, e0188593 (2017). doi: 10.1371/journal.pone.0188593
2. C. E. Delaney, A. T. Chen, *et al.* A histone H4 lysine 20 methyltransferase couples environmental cues to sensory neuron control of developmental plasticity. *Development.* **144**, 1273–1282 (2017). doi: 10.1242/dev.145722

3. S. S. Gang, M. L. Castelletto, *et al.* Targeted mutagenesis in a human-parasitic nematode. *PLoS Pathog.* **13**, e1006675 (2017). doi:10.1371/journal.ppat.1006675
4. J. F. Hultquist, J. Hiatt, *et al.* A CRISPR-Cas9 Genome Engineering Platform in Primary CD4+ T Cells for the Interrogation of HIV Host Factors *bioRxiv* 205500 (2017) doi: 10.1101/205500
5. S. Kim, S. R. F. Twigg, *et al.* Localized TWIST1 and TWIST2 basic domain substitutions cause four distinct human diseases that can be modeled in *Caenorhabditis elegans*. *Hum Mol Genet.* **26**, 2118–2132 (2017). doi: 10.1093/hmg/ddx107
6. N. Maio, K. S. Kim, *et al.* A Single Adaptable Cochaperone-Scaffold Complex Delivers Nascent Iron-Sulfur Clusters to Mammalian Respiratory Chain Complexes I-III. *Cell Metab.* **25**, 945–953, e6 (2017). doi: 10.1016/j.cmet.2017.03.010
7. A. Paix, A. Folkmann, *et al.* Precision genome editing using synthesis-dependent repair of Cas9-induced DNA breaks. *Proc Natl Acad Sci U S A.* **114**, E10745–E10754 (2017). doi: 10.1073/pnas.1711979114
8. A. Paix, A. Folkmann, *et al.* Precision genome editing using CRISPR-Cas9 and linear repair templates in *C. elegans*. *Methods.* 121–122, 86–93 (2017). doi: 10.1016/j.jymeth.2017.03.023
9. L. J. Rupp, K. Schumann, *et al.* CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. *Sci Rep.* **7**, 737 (2017). doi:10.1038/s41598-017-00462-8
10. Ž. Strezoska, M. Perkett, *et al.* High-content analysis screening for cell cycle regulators using arrayed synthetic crRNA libraries. *J. Biotechnol.* **251**, 189–200 (2017). doi: 10.1016/j.jbiotec.2017.04.017
11. X. M. van Wijk, S. Döhrmann, *et al.* Whole-Genome Sequencing of Invasion-Resistant Cells Identifies Laminin α 2 as a Host Factor for Bacterial Invasion. *MBio.* **8**, e02128-16 (2017). doi: 10.1128/mBio.02128-16

2016

1. T. A. Aguilera, M. Rafat, *et al.* Reprogramming the immunological microenvironment through radiation and targeting Axl. *Nat Commun.* **7**, 13898 (2016). doi: 10.1038/ncomms13898
2. R. Eggenschwiler, M. Moslem, *et al.* Improved bi-allelic modification of a transcriptionally silent locus in patient-derived iPSC by Cas9 nickase. *Sci Rep.* **6**, 38198 (2016). doi: 10.1038/srep38198
3. K. He, E. Chou, *et al.* Conjugation and evaluation of triazole-linked single guide RNA for CRISPR-Cas9 gene editing. *ChemBioChem.* **17**, 1809–1812 (2016). doi:10.1002/cbic.201600320
4. J. F. Hultquist, K. Schumann, *et al.* A Cas9 Ribonucleoprotein Platform for Functional Genetic Studies of HIV-Host Interactions in Primary Human T Cells. *Cell Reports* **17**, 1438–1452 (2016). doi:10.1016/j.celrep.2016.09.080
5. M. L. Kelley, Ž. Strezoska, *et al.* Versatility of chemically synthesized guide RNAs for CRISPR-Cas9 genome editing. *J. Biotechnol.* **233**, 74–83 (2016). doi:10.1016/j.jbiotec.2016.06.011
6. J. McCaffrey, J. Sibert, *et al.* CRISPR-CAS9 D10A nickase target-specific fluorescent labeling of double strand DNA for whole genome mapping and structural variation analysis. *Nucleic Acids Res.* **44**, e11 (2016). doi:10.1093/nar/gkv878
7. V. Müller, F. Rajer, *et al.* Direct identification of antibiotic resistance genes on single plasmid molecules using CRISPR/Cas9 in combination with optical DNA mapping. *Sci Rep.* **6**, 37938 (2016). doi:10.1038/srep37938
8. A. Paix, H. Schmidt, *et al.* Cas9-assisted recombineering in *C. elegans*: genome editing using in vivo assembly of linear DNAs. *Nucleic Acids Res.* **44**, e128 (2016). doi:10.1093/nar/gkw502
9. J. Tan, S. E. Martin. Validation of Synthetic CRISPR Reagents as a Tool for Arrayed Functional Genomic Screening. *PLoS One* **11**, e0168968 (2016). doi: 10.1371/journal.pone.0168968

2015

1. E. M. Anderson, A. Haupt, *et al.* Systematic analysis of CRISPR-Cas9 mismatch tolerance reveals low levels of off-target activity. *J. Biotechnol.* **211**, 56–65 (2015). doi:10.1016/j.jbiotec.2015.06.427
2. R. Barrangou, A. Birmingham, *et al.* Advances in CRISPR-Cas9 genome engineering: lessons learned from RNA interference. *Nucleic Acids Res.* **43**, 3407–3419 (2015). doi:10.1093/nar/gkv226
3. H. Ogiwara, M. Sasaki, *et al.* Targeting p300 addiction in CBP-deficient cancers causes synthetic lethality by apoptotic cell death due to abrogation of MYC expression. *Cancer Discov.* **6**, 430–445 (2015). doi:10.1158/2159-8290.CD-15-0754
4. S. Opp, D. A. S. A. Vieira, *et al.* MxB Is Not Responsible for the Blocking of HIV-1 Infection Observed in Alpha Interferon-Treated Cells. *J. Virol.* **90**, 3056–3064 (2015). doi:10.1128/JVI.03146-15
5. A. Paix, A. Folkmann, *et al.* High efficiency, homology-directed genome editing in *Caenorhabditis elegans* using CRISPR-Cas9 Ribonucleoprotein complexes. *Genetics.* **201**, 47–54 (2015) doi:10.1534/genetics.115.179382
6. G. Sivan, P. Ormanoglu, *et al.* Identification of Restriction Factors by Human Genome-Wide RNA Interference Screening of Viral Host Range Mutants Exemplified by Discovery of SAMD9 and WDR6 as Inhibitors of the Vaccinia Virus K1L-C7L- Mutant. *MBio.* **6**, e01122 (2015). doi:10.1128/mBio.01122-15
7. W. Deng, X. Shi, *et al.* CASFISH: CRISPR/Cas9-mediated in situ labeling of genomic loci in fixed cells. *Proc Natl Acad Sci U S A.* **112**, 11870–11875 (2015). doi:10.1073/pnas.1515692112

If you have any questions, contact

t +44 (0) 1223 976 000 (UK) **or** +1 800 235 9880 (USA); +1 303 604 9499 (USA)

f + 44 (0)1223 655 581

w horizondiscovery.com/contact-us **or** dharmacon.horizondiscovery.com/service-and-support

Horizon Discovery, 8100 Cambridge Research Park, Waterbeach, Cambridge, CB25 9TL, United Kingdom

All trademarks are the property of Horizon Discovery Company unless otherwise specified. ©2018 Horizon Discovery Group Company—All rights reserved. First published January 2017. UK Registered Head Office: Building 8100, Cambridge Research Park, Cambridge, CB25 9TL, United Kingdom.

horizon[™]
INSPIRED CELL SOLUTIONS